MedTrace Logo

Evaluation of the Effectiveness of a New Generation of Myopia Control Lens on the Progression of Myopia in Children Aged 6 to 14 Years

NCT07462897 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2026-04-23

No results posted yet for this study

Summary

The goal of this clinical investigation is to learn how much a new generation of myopia control lens (MCL1 - Myopia Control Lens 1) is helpful in reducing myopia progression in children from 6 to 14 yo. The main questions it aims to answer is: How much this new generation of lens, called MCL1, slows down the growth of the eye? Researchers will compare MCL1 to a former generation of myopia control lens (i.e. MCL2) but with better vision quality.

Participants will:

* Wear MCL1 on right eye and MCL2 on left eye for 6 months and MCL2 on rigth eye and MCL1 on left eye for the next 6 months;
* Visit the hospital at 6 and 12 months for tests;
* Answer weekly questionnaires on compliance wearing glasses, quality of vision and out-of-school activities.

Conditions

  • Myopia Progression

Interventions

DEVICE

MCL1

Myopia Control Lens 1 (MCL 1) is an ophthalmic lens intended to slow down eye growth in children.

DEVICE

MCL2

Myopia Control Lens 2 (MCL 2) is an ophthalmic lens intended to slow down eye growth in children.

Sponsors & Collaborators

  • Essilor International

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
6 Years
Max Age
14 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-18
Primary Completion
2028-04-30
Completion
2028-05-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07462897 on ClinicalTrials.gov